* Note: Prices are in Million (M) USD.
Description:
Dyne Therapeutics, Inc. is an innovative biotechnology company based in Waltham, Massachusetts, dedicated to revolutionizing the treatment of genetically-driven muscle diseases through its proprietary muscle-targeted delivery platform. The firm is advancing a robust pipeline of therapeutic candidates aimed at addressing significant unmet medical needs in this specialized field. With a strong focus on developing impactful therapies, Dyne Therapeutics is well-positioned to enhance patient outcomes and improve the quality of life for individuals suffering from muscle disorders, making it a compelling investment opportunity within the biotechnology sector.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $574 M
Debt : $104 M
EBITDA : $-433 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 18 overlapping fiscal years (max 20).Average Free Cash Flow: $16 M
Average Revenue: $956 M
Revenue Converted To Free Cash Flow (%): 1.7%
Since Free Cash Flow (FCF) to Revenue percentage is less than 15, 1 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $0 M
Revenue 5 Years Ago (2019-12-31): $0 M
Total Growth over 5 Years: 0.0%
5-Year Revenue CAGR (Historical): 0.0%
Forward 5-Year CAGR (Tapered): 0.0%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $94 M
Share Count 5 Years Ago (2020-12-31): $47 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-3.40
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-3.40
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 17 valid ROE years (max 20).Average ROE: -46.4%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $20.24
52-Week Low: $6.36
Threshold Price (15% Above 52-Week Low): $7.31
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $2,891 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2017-12-31): $3.83
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 8 points to above Dyne Therapeutics Inc (DYN) stock.
Fair Value PE 9, Industry Based PE 15, RCFC Based PE 1.71, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 4 values, average assigned is 11.05. The fair value of Dyne Therapeutics Inc (DYN) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
